Cediranib Versus Olaparib in Recurrent Platinum-Sensitive Ovarian Cancer

Special Reports, Gynecologic Cancers (Issue 1), Volume 1, Issue 1

Jyoti D. Patel, MD, discusses a phase II trial that looked at olaparib in combination with cediranib versus olaparib alone in recurrent platinum-sensitive ovarian cancer.

Jyoti D. Patel, MD, ASCO expert, associate professor, Northwestern University Feinberg School of Medicine, discusses a phase II trial that looked at olaparib in combination with cediranib versus olaparib alone in recurrent platinum-sensitive ovarian cancer. This trial was presented by Dr. Joyce Liu at the 2014 ASCO Annual Meeting.

Learn more about potentially promising treatments for ovarian cancer > >